Olmetor AM 5 mg+20 mg (Tablet)
Unit Price: ৳ 10.00 (3 x 10: ৳ 300.00)
Strip Price: ৳ 100.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Amlodipine besilate olmesartan medoxomil |
| Company | Euro pharma ltd |
| Also available as |
Indications
- Treatment of hypertension alone or with other antihypertensive agents
- Lowering blood pressure
- Initial therapy for patients likely to need multiple antihypertensive agents
- Individualized blood pressure goals
- Risk-based blood pressure goals
Pharmacology
- Amlodipine as a dihydropyridine calcium channel blocker
- Greater effect on vascular smooth muscle cells than on cardiac muscle cells
- Peripheral arterial vasodilator
- Olmesartan Medoxomil blocks vasoconstrictor and aldosterone-secreting effects of angiotensin II
- Competitive inhibitor of the AT1 receptor
Dosage & Administration
- Substitute individually titrated components for patients on Amlodipine and Olmesartan Medoxomil
- Initial therapy with 5/20 mg once daily for 1 to 2 weeks
- Titration up to a maximum of 10/40 mg once daily
- Lower starting dose of Amlodipine in elderly patients
- Not recommended in patients >75 years old
Interaction
- Attenuation of antihypertensive effect by NSAIDs including selective COX-2 inhibitors
- Close monitoring of blood pressure, renal function, and electrolytes in patients on combination therapy
Contraindications
- Co-administration with Aliskiren in patients with diabetes
Side Effects
- Peripheral edema
- Headache
- Flushing
- Dizziness
- Sprue-like enteropathy
Pregnancy & Lactation
- Pregnancy Category D
- Not for use in 2nd and 3rd trimester
- Discontinuation when pregnancy is detected
- Unknown excretion in human milk
- Consideration of adverse effects on the nursing infant
Precautions & Warnings
- Risk for hypotension in volume- or salt-depleted patients
- Risk for vasodilation in patients with severe aortic stenosis
- Risk for increased frequency, duration, or severity of angina or acute Ml in patients with severe obstructive coronary artery disease
Use in Special Populations
- Safety and effectiveness not established in pediatric patients
- No overall differences in safety or effectiveness observed between subjects 65 years of age or older and younger subjects
- No studies in patients with renal impairment
- Initial therapy not recommended in hepatically impaired patients
Overdose Effects
- No information on overdose in humans
Therapeutic Class
- Combined antihypertensive preparations
Storage Conditions
- Store below 30°C
- Keep away from light
- Keep out of the reach of children